Terrence L. Fisher, Ph.D.
Affiliations: | 2002 | University of Rochester, Rochester, NY |
Area:
ImmunologyGoogle:
"Terrence Fisher"Parents
Sign in to add mentor| John G. Frelinger | grad student | 2002 | Rochester | |
| (Analysis of the immune response to antigens expressed by tumors: Application to prostate -specific antigen and human kallikrein 2.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Greengard E, Williams R, Moriarity B, et al. (2024) A phase 1/2 study of pepinemab in children, adolescents, or young adults with recurrent or refractory solid tumors: A children's oncology group consortium report (ADVL1614). Pediatric Blood & Cancer. e30938 |
| Shafique M, Fisher TL, Evans EE, et al. (2021) A Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Shafique MR, Fisher TL, Evans EE, et al. (2020) Interim results from a phase Ib/II study of pepinemab in combination with avelumab in advanced NSCLC patients following progression on prior systemic and/or anti-PDx therapies. Journal of Clinical Oncology. 38: 75-75 |
| Ruffolo LI, Ullman NA, Dale B, et al. (2020) Antibody blockade of semaphorin 4D to sensitize pancreatic cancer to immune checkpoint blockade. Journal of Clinical Oncology. 38: 26-26 |
| Shafique MR, Fisher TL, Evans EE, et al. (2020) Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC. Journal of Clinical Oncology. 38: 3011-3011 |
| Lowe MC, Olson B, Martinez A, et al. (2020) Integrated biomarker study of neoadjuvant pepinemab and nivolumab in patients with resectable metastatic melanoma. Journal of Clinical Oncology. 38: 10061-10061 |
| Evans EE, Lesinski GB, Fisher TL, et al. (2020) Abstract A15: Integrated biomarker trials to evaluate myeloid and lymphoid composition of HNSCC and solid tumors treated with pepinemab and combinations with checkpoint inhibitors Clinical Cancer Research. 26 |
| Lowe MC, Lesinski GB, Delman KA, et al. (2019) Pilot integrated biomarker study of VX15/2503 in combination with ipilimumab and/or nivolumab in patients with resectable metastatic melanoma. Journal of Clinical Oncology. 37 |
| Greengard EG, Williams RL, Liu X, et al. (2019) A phase I/II trial of VX15/2503 in children, adolescents, and young adults with relapsed or refractory solid tumors (ADVL1614). Journal of Clinical Oncology. 37 |
| Shafique MR, Fisher TL, Evans EE, et al. (2019) Preliminary results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC. Journal of Clinical Oncology. 37: 2601-2601 |